Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

obinutuzumab

- PMLiVE

Roche and Prothena set to advance Parkinson’s disease candidate into phase 2b

Drug moves into late-stage testing despite failing to hit primary endpoint in previous trial

- PMLiVE

Roche to collaborate with Dyno on gene therapies for CNS/liver diseases

Dyno will use its CapsidMap platform to develop novel AAV vectors for improved gene therapies

- PMLiVE

Roche’s Ocrevus boasts positive long-term data in MS

After two years of treatment 75% of patients had no evidence of disease activity

Roche Basel Switzerland

Roche plans to launch rapid COVID-19 antigen test later this month

Swiss pharma also intends to file for emergency approval in the US

- PMLiVE

NICE recommends Roche’s Polivy for B-cell lymphoma

Cost-effectiveness agency approves drug following initial rejection earlier this year

- PMLiVE

Roche, Regeneron partner on COVID-19 antibody cocktail

Collaboration agreement will bolster global development and manufacturing capabilities

Roche Basel Switzerland

Roche’s Soliris rival Enspryng bags FDA approval

Drug is second to be approved for the treatment of NMOSD

- PMLiVE

AbbVie, Roche’s Venclyxto combo reduces risk of death in first-line AML

Data from the trial has been published in the New England Journal of Medicine

Roche Basel Switzerland

Roche scores FDA approval for SMA drug risdiplam, now named Evrysdi

Drug poised to challenge rivals Spinraza and Zolgensma

- PMLiVE

Tecentriq combo fails in advanced triple negative breast cancer

Tecentriq plus paclitaxel failed to improve progression-free survival

Roche Basel Switzerland

Roche’s Tecentriq combo scores FDA approval for melanoma

Drug approved for patients with BRAF protein mutations

- PMLiVE

Roche pays $120m upfront for UCB’s anti-tau Alzheimer’s drug

Milestone payments could reach up to $2bn

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links